Question 1

What is Shanghai Henlius Biotech?

Accepted Answer

Shanghai Henlius Biotech is a Company.

Question 2

How often does Shanghai Henlius Biotech appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Shanghai Henlius Biotech first tracked by Ergen?

Accepted Answer

First tracked on Apr 29, 2026.

Question 4

When was Shanghai Henlius Biotech last mentioned in news?

Accepted Answer

Last active on May 17, 2026.

Question 5

What is Shanghai Henlius Biotech's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Shanghai Henlius Biotech in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Shanghai Henlius Biotech?

Accepted Answer

POHERDY Biosimilar Approved in Europe (Apr 29, 2026, 6 articles).

Question 8

How did the "POHERDY Biosimilar Approved in Europe" event impact Shanghai Henlius Biotech?

Accepted Answer

Shanghai Henlius Biotech, in collaboration with Organon, received International — European Commission marketing authorization for POHERDY, its biosimilar to PERJETA, expanding its global portfolio and market access.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.